Galvus
(Vildagliptin)ApprovedSmall molecule
NovartisVildagliptin is used to treat type 2 diabetes by helping the pancreas produce more insulin when blood sugar levels are high, and it works by preventing the breakdown of hormones that regulate blood sugar.[2] Galvus is currently approved and in use across 16 indications[4].[1]
Galvus is one of 471 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.
16
Indications
151
Total Trials
6
Active Trials
470
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Galvus
NovartisApproved
Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes72 trials
Show 69 more trials
Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
Completed·—·Phase 4·NCT02145611·50 enrolled
Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes
Completed·—·Phase 4·NCT04916093·60 enrolled
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Active, not recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 4·NCT06851962·504 enrolled
Type 2 Diabetes Mellitus11 trials
Show 8 more trials
Metformin6 trials
Show 3 more trials
Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
Completed·CCentre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète·Phase 4·NCT01757587·39 enrolled
Type 2 Diabetic Patients4 trials
Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients
Completed·—·N/A·NCT06068686·70 enrolled
Show 1 more trial
Renal insufficiency4 trials
44 more indications
Lip3 trials
Type 1 Diabetes2 trials
Function2 trials
ESS2 trials
Transplantation2 trials
Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period
Unknown status·—·Phase 3·NCT02849899·186 enrolled
Efficacy and Safety2 trials
Insulin Secretion2 trials
GLP-11 trial
Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
Completed·—·Phase 1·NCT02749032·24 enrolled
PreDiabetes1 trial
Patient Preference1 trial
Gestational Diabetes1 trial
Metabolic Syndrome1 trial
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
Unknown status·—·Phase 4·NCT04485845·39 enrolled
Neuropathy1 trial
Efficacy1 trial
Type 1 Diabetes Mellitus1 trial
Cognition1 trial
ART1 trial
Cardiovascular1 trial
Congestive Heart Failure1 trial
Prevention1 trial
Drug1 trial
Cognitive Protective Effect of Newer Antidiabetic Drugs
Unknown status·—··NCT05347459·100 enrolled
Impaired glucose tolerance1 trial
Safety and Efficacy1 trial
Diabetes Mellitus1 trial
Empagliflozin1 trial
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
Completed·—·N/A·NCT06313008·120 enrolled
Major Depressive Disorder1 trial
Inflammation1 trial
Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD
Completed·—·Phase 4·NCT03693560·80 enrolled
Diabetes, Type 21 trial
Treatment1 trial
Unspecified3 trials
Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor
Completed·—·Phase 4·NCT03178591·43 enrolled
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Galvus drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Vildagliptin. EMBL-EBI & Wellcome Sanger Institute.
- [5]